Severe adverse cutaneous reactions to drugs

New England Journal of Medicine

Volumn 331, Issue 19, 1994, Pages 1272-1285

  Roujeau, Jean Claude ^a   Stern, Robert S ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINOPENICILLANIC ACID; ALLOPURINOL; BARBITURIC ACID DERIVATIVE; BENOXAPROFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CHLORMEZANONE; COTRIMOXAZOLE; DICLOFENAC; ETHAMBUTOL; FENBUFEN; HYDANTOIN; IBUPROFEN; ISOXICAM; KETOPROFEN; PHENYLBUTAZONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SALAZOSULFAPYRIDINE; SULFADIAZINE; SULFADOXINE; SULINDAC; TENOXICAM; THIOACETAZONE; TIAPROFENIC ACID; UNINDEXED DRUG; VANCOMYCIN;

ANGIONEUROTIC EDEMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG HYPERSENSITIVITY; EOSINOPHILIA; HUMAN; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT PLANNING; URTICARIA; VASCULITIS;

ANGIONEUROTIC EDEMA; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; DRUG THERAPY; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; SERUM SICKNESS; STEVENS-JOHNSON SYNDROME; VASCULITIS;

EID: 0028077408     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199411103311906     Document Type: Review

References (143)

1. Chan HL, Stern RS, Arndt KA, The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-47
2. Corre KA, Spielberg TE Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point. Ann Emerg Med 1988; 17: 145-149
3. Roujeau JC, Guillaume JC, Febre JP, Penso D, Flechet ML, Girre JP Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37-42
4. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451-458
5. Bigby M, Jick S, Jick H, Arndt K Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-3363
6. Leape LL, Brennan TA, Laird N, The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377-384
7. Alanko K, Stubb S, Kauppinen K Cutaneous drug reactions: clinical types and causative agents: a five-year survey of in-patients (1981-1985). Acta Derm Venereol Suppl (Stockh) 1989; 69: 223-226
8. Ives TJ, Bentz EJ, Gwyther RE Dermatologic adverse drug reactions in a family medicine setting. Arch Fam Med 1992; 1: 241-245
9. Varga J, Vitto J, Jimenez SA The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med 1992; 116: 140-147
10. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979; 242: 623-632
11. Turner WM The Food and Drug Administration algorithm: special workshop -- regulatory. Drug Inf J 1984; 18: 259-266
12. Louik C, Lacouture PG, Mitchell AA, A study of adverse reaction algorithms in a drug surveillance program. Clin Pharmacol Ther 1985; 38: 183-187
13. Ressler C, Mendelson LM Skin test for diagnosis of penicillin allergy -- current status. Ann Allergy 1987; 59: 167-170
14. Bruynzeel D, van Ketel W Skin tests in the diagnosis of maculo-papular drug eruptions. Semin Dermatol 1987; 6: 119-124
15. Shear NH Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990; 126: 94-97
16. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-289
17. Shear NH, Spielberg SP Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82: 1826-1832
18. Revuz J, Penso D, Roujeau JC, Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-1165
19. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-842
20. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96
21. Stevens AM, Johnson FC A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922; 24: 526-533
22. Lyell A Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361
23. Bergoend H, Loffler A, Amar R, Maleville J Reactions cutanees survenues au cours de la prophylaxie de masse de la meningite cerebro-spinale par un sulfamide long-retard (a propos de 997 cas). Ann Dermatol Syphiligr (Paris) 1968; 95: 481-490
24. Ruiz-Maldonado R Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13: 623-635
25. Huff JC, Weston WL, Tonnesen MG Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8: 763-775
26. Roupe G, Ahlmen M, Fagerberg B, Suurkula M Toxic epidermal necrolysis with extensive mucosal erosions of the gastrointestinal and respiratory tracts. Int Arch Allergy Appl Immunol 1986; 80: 145-151
27. Timsit JF, Mion G, Rouyer N, Le Gulluche Y, Carsin H Bronchopulmonary distress associated with toxic epidermal necrolysis. Intensive Care Med 1992; 18: 42-44
28. Chosidow O, Delchier J-C, Chaumette MT, Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 1991; 337: 928-928
29. Wilkins J, Morrison L, White CR Jr Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson/toxic epidermal necrolysis spectrum. Dermatol Clin 1992; 10: 571-582
30. Binaghi M, Kosos M, Saiag P, Roujeau JC, Coscas G Atteinte oculaire au cours du syndrome de Lyell: incidence, evolution, pronostic. Ophtalmologie 1988; 2: 121-122
31. Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881-887
32. Westly ED, Wechsler HL Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984; 120: 721-726
33. Jordan MH, Lewis MS, Jeng JG, Rees JM Treatment of toxic epidermal necrolysis by burn units: another market or another threat? J Burn Care Rehabil 1991; 12: 579-581
34. Marks J Erythroderma and its management. Clin Exp Dermatol 1982; 7: 415-422
35. Melish ME, Glasgow LA The staphylococcal scalded-skin syndrome: development of an experimental model. N Engl J Med 1970; 282: 1114-1119
36. Roujeau JC, Bioulac-Sage P, Bourseau C, Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127: 1333-1338
37. Mutasim DF, Pelc NJ, Anhalt GJ Paraneoplastic pemphigus. Dermatol Clin 1993; 11: 473-481
38. Bottiger LE, Strandberg I, Westerholm B Drug-induced febrile mucocutaneous syndrome with a survey of the literature. Acta Med Scand 1975; 198: 229-233
39. Naldi L, Locati F, Marchesi I, Cainelli T Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1103-1104
40. Strom BL, Carson JL, Halpern AC, A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991; 127: 831-838
41. House RA, Jakubovic H, Wong L, Holness DL Work-related toxic epidermal necrolysis? J Occup Med 1992; 34: 135-139
42. Nethercott JR, Choi BC Erythema multiforme (Stevens-Johnson syndrome) -- chart review of 123 hospitalized patients. Dermatologica 1985; 171: 383-396
43. Stern RS, Chan HL Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21: 317-322
44. Hellgren U, Rombo L, Berg B, Carlson J, Wilholm BE Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis. BMJ 1987; 295: 365-366
45. Askmark H, Wiholm B-E Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990; 81: 131-140
46. Burge SM, Dawber RPR Stevens-Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus. J Am Acad Dermatol 1985; 13: 665-666
47. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1171-1173
48. Billingham RE, Streilein JW Toxic epidermal necrolysis and homologous disease in hamsters. Arch Dermatol 1968; 98: 528-539
49. Peck GL, Elias PM, Graw RG Jr Graft-versus-host reaction and toxic epidermal necrolysis. Lancet 1972; 2: 1151-1153
50. Villada G, Roujeau JC, Cordonnier C, Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23: 870-875
51. McDonald BJ, Singer JW, Bianco JA Toxic epidermal necrolysis possibly linked to aztreonam in bone marrow transplant patients. Ann Pharmacother 1992; 26: 34-35
52. Coopman SA, Johnson RA, Platt R, Stern RS Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 328: 1670-1674
53. Porteous DM, Berger TG Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 1991; 127: 740-741
54. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-574
55. Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993; 129: 1059-1059
56. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722-727
57. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-184
58. Merot Y, Gravallese E, Guillen FJ, Murphy GF Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis: report of a case. Arch Dermatol 1986; 122: 455-458
59. Heng MC, Allen SG Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects. J Am Acad Dermatol 1991; 25: 778-786
60. Villada G, Roujeau JC, Clerici T, Bourgault I, Revuz J Immunopathology of toxic epidermal necrolysis: keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1992; 128: 50-53
61. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129: 466-468
62. Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2171-2175 [Erratum, JAMA 1987;258:1894.]
63. Demling RH Burns. N Engl J Med 1985; 313: 1389-1398
64. Sheretz EF, Jegasothy BV, Lazarus GS Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis: report of a patient treated with corticosteroid “pulse therapy.” J Am Acad Dermatol 1985; 12: 178-181
65. Rzany B, Schmitt H, Schopf E Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol Suppl (Stockh) 1991; 71: 171-172
66. Kim PS, Goldfarb IW, Gaisford JC, Slater H Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil 1983; 4: 91-100
67. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512
68. Weston WL, Oranje AP, Rasmussen JE, Corticosteroids for erythema multiforme? Pediatr Dermatol 1989; 6: 229-250
69. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121: 1548-1549
70. Renfro L, Grant-Kels JM, Daman LA Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989; 28: 441-444
71. Pelekanos J, Camfield P, Camfield C, Gordon K Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia 1991; 32: 554-559
72. Pellock JM Carbamazepine side effects in children and adults. Epilepsia 1987; 28: Suppl 3: S64-S70
73. Rapp RP, Norton JA, Young B, Tibbs PA Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery 1983; 13: 272-275
74. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990; 323: 497-502
75. Haruda F Phenytoin hypersensitivity: 38 cases. Neurology 1979; 29: 1480-1485
76. Livingston S, Villamater C, Sakata Y, Pauli LL Use of carbamazepine in epilepsy: results in 87 patients. JAMA 1967; 200: 204-208
77. Lupton GP, Odom RB The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979; 1: 365-374
78. Serre H, Sany J, Rosenberg F Les effets secondaires de la chrysotherapie. Ann Med Interne (Paris) 1976; 127: 552-559
79. Tomecki KJ, Catalano CJ Dapsone hypersensitivity: the sulfone syndrome revisited. Arch Dermatol 1981; 117: 38-39
80. Spielberg SP, Shear NH, Cannon M, Hutson NJ, Gunderson K In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann Intern Med 1991; 114: 720-724
81. Rijlaarsdam U, Scheffer E, Meijer CJ, Kruyswijk MR, Willemze R Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24: 216-220
82. Rosenthal CJ, Noguera CA, Coppola A, Kapelner SN Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982; 49: 2305-2314
83. Ray-Chaudhuri K, Pye IF, Boggild M Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure. Neurology 1989; 39: 436-438
84. Parker WA, Shearer CA Phenytoin hepatotoxicity: a case report and review. Neurology 1979; 29: 175-178
85. Maguire JH, Wettrell G, Rane A Apparently normal phenytoin metabolism in a patient with phenytoin-induced rash and lymphadenopathy. Br J Clin Pharmacol 1987; 24: 554-557
86. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631-634
87. Beran RG Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163-165
88. Pirmohamed M, Graham A, Roberts P, Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32: 741-749
89. Wilson JT, Hojer B, Tomson G, Rane A, Sjoqvist F High incidence of a concentration-dependent skin reaction in children treated with phenytoin. BMJ 1978; 1: 1583-1586
90. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13-17
91. Murphy JM, Mashman J, Miller JD, Bell JB Suppression of carbamazepine-induced rash with prednisone. Neurology 1991; 41: 144-145
92. Gupta A, Eggo MC, Uetrecht JP, Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56-67
93. Fauci AS, Haynes B, Katz P The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978; 89: 600-676
94. Calabrese LH, Michel BA, Bloch DA, The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33: 1108-1113
95. von Pirquet C, Schick B. Serum sickness. Baltimore: Williams & Wilkins, 1951.
96. Bielory L, Yancey KB, Young NS, Frank MM, Lawley TJ Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol 1985; 13: 411-417
97. Warrington RJ, Martens CJ, Rubin M, Rutherford WJ, Aoki FY Immunologic studies in subjects with a serum sickness-like illness after immunization with human diploid cell rabies vaccine. J Allergy Clin Immunol 1987; 79: 605-610
98. Wintroub BU, Stern R Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol 1985; 13: 167-179
99. Dubost JJ, Souteyrand P, Sauvezie B Drug-induced vasculitides. Baillieres Clin Rheumatol 1991; 5: 119-138
100. Brasile L, Kremer JM, Clarke JL, Cerilli J Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med 1989; 87: 74-80
101. Falk RJ, Jennette JC Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-1657
102. Ekenstam EAF, Callen JP Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol 1984; 120: 484-489
103. Sanchez NP, Van Hale HM, Su WP Clinical and histopathologic spectrum of necrotizing vasculitis: report of findings in 101 cases. Arch Dermatol 1985; 121: 220-224
104. Van Hale HM, Gibson LE, Schroeter AL Henoch-Schonlein vasculitis: direct immunofluorescence study of uninvolved skin. J Am Acad Dermatol 1986; 15: 665-670
105. Hoffman GS, Kerr GS, Leavitt RY, Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
106. D'Cruz D, Hughes G Systemic vasculitis: new tests, new treatments. BMJ 1992; 304: 269-270
107. Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah CS Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci 1989; 297: 216-219
108. Carrasco MD, Riera C, Clotet B, Grifol M, Foz M Cutaneous vasculitis associated with propylthiouracil therapy. Arch Intern Med 1987; 147: 1677-1677
109. Horton RC, Sheppard MC, Emery P Prophylthiouracil-induced systemic lupus erythematosus. Lancet 1989; 2: 568-568
110. Dolman KM, Gans RO, Vervaat TJ, Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651-652
111. Dwyer JM, Kenicer K, Thompson BT, Vasculitis and retinoids. Lancet 1989; 2: 494-496
112. Huminer D, Cohen JD, Majadla R, Dux S Hypersensitivity vasculitis due to ofloxacin. BMJ 1989; 299: 303-303
113. Taylor RJ Hypersensitivity vasculitis occurring in a patient receiving immunotherapy. J Allergy Clin Immunol 1991; 87: 889-890
114. Heckbert SR, Stryker WS, Coltin K, Manson JE, Platt R Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132: 336-342
115. Platt R, Dreis MW, Kennedy DL, Kuritsky JN Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole. J Infect Dis 1988; 158: 474-477
116. Yen MC, Piszczek JE, Mintzer DL Serum sickness-like syndrome associated with propranolol therapy. Postgrad Med 1983; 74: 291-294
117. Puyana J, Urena V, Quirce S, Fernandez-Rivas M, Cuevas M, Fraj J Serum sickness-like syndrome associated with minocycline therapy. Allergy 1990; 45: 313-315
118. Noel J, Rosenbaum LH, Gangadharan V, Stewart J, Galens G Serum sickness-like illness and leukocytoclastic vasculitis following intracoronary arterial streptokinase. Am Heart J 1987; 113: 395-397
119. Bauer KA Coumarin-induced skin necrosis. Arch Dermatol 1993; 129: 766-768
120. Comp PC Coumarin-induced skin necrosis: incidence, mechanisms, management and avoidance. Drug Saf 1993; 8: 128-135
121. Teepe RG, Broekmans AW, Vermeer BJ, Nienhuis AM, Loeliger EA Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122: 1408-1412
122. Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 416-425
123. Schramm W, Spannagl M, Bauer KA, Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993; 129: 753-756
124. Miletich J, Sherman L, Broze G Jr Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
125. Grimaudo V, Gueissaz F, Hauert J, Sarraj A, Kruithof EK, Bachmann F Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ 1989; 298: 233-234
126. MacLean JA, Moscicki R, Bloch KJ Adverse reactions to heparin. Ann Allergy 1990; 65: 254-259
127. Tuneu A, Moreno A, de Moragas JM Cutaneous reactions secondary to heparin injections. J Am Acad Dermatol 1985; 12: 1072-1077
128. Kelly RA, Gelfand JA, Pincus SH Cutaneous necrosis caused by systemically administered heparin. JAMA 1981; 246: 1582-1583
129. Kelton JG, Sheridan D, Santos A, Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930
130. Bochner BS, Lichtenstein LM Anaphylaxis. N Engl J Med 1991; 324: 1785-1790
131. Horan RF, Schneider LC, Sheffer AL Allergic skin disorders and mastocytosis. JAMA 1992; 268: 2858-2868
132. International Rheumatic Fever Study Group. Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. Lancet 1991; 337: 1308-1310
133. Megerian CA, Arnold JE, Berger M Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment. Laryngoscope 1992; 102: 256-260
134. Hedner T, Samuelsson O, Lunde H, Lindholm L, Andren L, Wiholm BE Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304: 941-946
135. Thompson T, Frable MA Drug-induced, life-threatening angioedema revisited. Laryngoscope 1993; 103: 10-12
136. Bielory L, Lee SS, Holland CL, Jaker M Long-acting ACE inhibitor-induced angioedema. Allergy Proc 1992; 13: 85-87
137. Slater EE, Merrill DD, Guess HA, Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 967-970
138. Anderson MW, deShazo RD Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol 1990; 85: 856-858
139. Verresen L, Waer M, Vanrenterghem Y, Michielsen P Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990; 336: 1360-1362
140. Parnes EL, Shapiro WB Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 1991; 40: 1148-1152
141. Brunet P, Jaber K, Berland Y, Baz M Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating AN69 membrane and angiotensin I-converting enzyme inhibitors. Am J Kidney Dis 1992; 19: 444-447
142. Kessler DA Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-2768
143. Moore N, Biour M, Paux G, Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2: 1056-1058